Any current/future new fundraising through debt or equity?

There is no mention of any current or future fundraising through debt or equity in the provided transcript. The company emphasizes being a cash-rich entity focused on creating long-term value for shareholders. Investments for growth and new product development are being funded through existing profits and careful cost management. No guidance or announcements regarding raising funds via debt or equity were discussed during the call.

Any current/future capex/capital investment/strategic investment?

The company is focused on continuous investment in new product development, specifically in Horizon 2 and Horizon 3 solutions, to diversify and sustain future growth. Recent investments have been approved by the board for product development, including anti-fraud.ai and enterprise security solutions like SWG, secure web gateway, malware analysis platforms, and threat Intel platforms. R&D spending is maintained steadily, with incremental hiring for specialized skills but no significant increase expected in overall R&D costs. Investments in sales organization are ongoing, especially to target mi

Future growth expectations in sales/revenue/volumes?

Quick Heal is focusing on diversifying from a core consumer antivirus (AV) business (currently ~62% revenue) towards enterprise security solutions (38%), aiming for balanced growth. New product launches like AntiFraud.ai and enterprise solutions (SWG, cloud security access broker, malware analysis, threat intel) are expected to grow revenue share from 10-15% currently to higher levels over time. Management is confident these new products will gain significant revenue share, with aspirations to diversify revenue mix to 30-50% from new offerings in the medium term. The enterprise business is evo

Future growth expectations in earnings/operating earnings/profits/EPS?

Quick Heal is focused on consistent, predictable profitable growth without providing specific guidance on timing or targets. The company is reinvesting margins and profits into new enterprise security technologies, expecting long-term growth. New products like AntiFraud.ai and enterprise solutions are in early revenue stages, contributing 10-15% of revenues and expected to diversify revenue streams going forward. They are expanding into mid-market and lower large enterprise segments, supported by enhanced sales organization. EBITDA has improved compared to last year, with early signs of profit

Quick Heal Technologies LtdQ2 FY25IT - Software

Quick Heal Technologies Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹151.55Market Cap: ₹821 CrSector: IT - Software

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Quick Heal is focusing on diversifying from a core consumer antivirus (AV) business (currently ~62% revenue) towards enterprise security solutions (38%), aiming for balanced growth.
New product launches like AntiFraud.ai and enterprise solutions (SWG, cloud security access broker, malware analysis, threat intel) are expected to grow revenue share from 10-15% currently to higher levels over time.
Management is confident these new products will gain significant revenue share, with aspirations to diversify revenue mix to 30-50% from new offerings in the medium term.
The enterprise business is evolving with growth expected from pivoting sales motion towards mid-market and lower large enterprises, supported by new leadership hiring.
Despite current near term headwinds in consumer business and industry degrowth, these new product launches and market expansion are viewed as future growth drivers.
No specific revenue guidance provided, but emphasis on consistent, predictable profitable growth over next 2-3 years with long-term investment horizon.

Margin guidance

Category 3

Quick Heal is focused on consistent, predictable profitable growth without providing specific guidance on timing or targets.
The company is reinvesting margins and profits into new enterprise security technologies, expecting long-term growth.
New products like AntiFraud.ai and enterprise solutions are in early revenue stages, contributing 10-15% of revenues and expected to diversify revenue streams going forward.
They are expanding into mid-market and lower large enterprise segments, supported by enhanced sales organization.
EBITDA has improved compared to last year, with early signs of profitability returning despite headwinds in consumer business.
R&D and sales investments are ongoing but controlled; product development cycles globally often take 10-15 years to break even.
Management maintains a long-term view, with emphasis on building scalable and sustainable cybersecurity solutions to increase market share and profitability over next 2-3 years.

See what Quick Heal Technologies Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or future fundraising through debt or equity in the provided transcript.
The company emphasizes being a cash-rich entity focused on creating long-term value for shareholders.
Investments for growth and new product development are being funded through existing profits and careful cost management.
No guidance or announcements regarding raising funds via debt or equity were discussed during the call.

Order book

The transcript from the provided pages does not contain specific information about Quick Heal Technologies Limited's current or expected order book or pending orders. However, relevant insights include: - The company is focused on expanding its product portfolio, including the newly launched AntiFraud.ai product targeting the consumer segment. - There is a stated emphasis on growth in both consumer and enterprise segments, with strategic pivots towards mid-market and large enterprises. - The business is currently investing in new technologies and sales capacity to drive growth. - Revenue from new products has already started getting generated this quarter. - The company does not disclose specific market share targets or order book details but is focused on capturing a percentage of the serviceable addressable market (operable market). No explicit figures or order backlog details were mentioned in the transcript.

See what Quick Heal Technologies Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is focused on continuous investment in new product development, specifically in Horizon 2 and Horizon 3 solutions, to diversify and sustain future growth.
Recent investments have been approved by the board for product development, including anti-fraud.ai and enterprise security solutions like SWG, secure web gateway, malware analysis platforms, and threat Intel platforms.
R&D spending is maintained steadily, with incremental hiring for specialized skills but no significant increase expected in overall R&D costs.
Investments in sales organization are ongoing, especially to target mid-market and lower-end large enterprises.
The company expenses all R&D investments in the same financial year rather than capitalizing them.
Focus on optimizing return on R&D investments and making tactical investments as required.
No specific numeric guidance on capex or strategic investments was disclosed for the current or future periods.

Track Quick Heal Technologies Ltd — get its next earnings analysis in your feed

How does Quick Heal Technologies Ltd rank vs peers in IT - Software?

Pro feature

ThisQuick Heal Technologies Ltd

Rev 3Mar 3

See where Quick Heal Technologies Ltd sits in IT - SoftwareSee which companies these are, and every other name in the sector.Open rankings

How does Quick Heal Technologies Ltd rank in IT - Software?

Compare Quick Heal Technologies Ltd against every IT - Software company (Q2 FY25) on revenue, margins and earnings-call signals.

View IT - Software leaderboard →

What Quick Heal Technologies Ltd's management said in earlier quarters

Others in IT - Software this season

Delaplex (Q1 FY27)
H2 FY26 total income (quarterly equivalent): ₹340.4 Mn vs ₹328.4 Mn in H2 FY25, a 3.66% YoY increase. Key investor presentation takeaways from Delaplex Ltd's Q1
Softtech Enginee (Q2 FY26)
Standalone: Rs 25.71 Cr (up from Rs 22.93 Cr in Q2 FY 2024-25) — approx. Key investor presentation takeaways from Softtech Engineers Ltd's Q2 FY26 investor pres
Systango Tech (Q2 FY26)
Year-on-Year (YoY) revenue growth for H1-FY26 is 58.0% compared to H1-FY25 revenue of INR 288 million. Key investor presentation takeaways from Systango Technol
3i Infotech Ltd (Q2 FY26)
Q2 FY26 consolidated revenue from operations: ₹174.9 crore, a 2.5% increase quarter-on-quarter (QoQ) but a 2% decrease year-on-year (YoY) from ₹177.6 crore in…

Compare:vs Infosys vs Wipro vs Tech Mahindra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Quick Heal Technologies Ltd Q2 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Quick Heal Technologies Ltd rank in IT - Software?

Continue your research

What Quick Heal Technologies Ltd's management said in earlier quarters

Others in IT - Software this season